KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $3.4 million.

  • NovoCure's Gains from Investment Securities fell 4832.0% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $28.6 million, marking a year-over-year increase of 864.24%. This contributed to the annual value of $23.5 million for FY2024, which is 2989.54% up from last year.
  • NovoCure's Gains from Investment Securities amounted to $3.4 million in Q3 2025, which was down 4832.0% from $13.8 million recorded in Q2 2025.
  • In the past 5 years, NovoCure's Gains from Investment Securities registered a high of $13.8 million during Q2 2025, and its lowest value of -$4.0 million during Q3 2023.
  • In the last 5 years, NovoCure's Gains from Investment Securities had a median value of $3.6 million in 2022 and averaged $4.1 million.
  • The largest annual percentage gain for NovoCure's Gains from Investment Securities in the last 5 years was 34749.58% (2023), contrasted with its biggest fall of 24041.73% (2023).
  • Over the past 5 years, NovoCure's Gains from Investment Securities (Quarter) stood at $9.8 million in 2021, then crashed by 44.42% to $5.4 million in 2022, then soared by 71.6% to $9.3 million in 2023, then crashed by 31.21% to $6.4 million in 2024, then tumbled by 46.49% to $3.4 million in 2025.
  • Its Gains from Investment Securities was $3.4 million in Q3 2025, compared to $13.8 million in Q2 2025 and $5.0 million in Q1 2025.